Integration of Liquid Biopsy and Immunotherapy: Opening a New Era in Colorectal Cancer Treatment

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2023 Dec 11

PMID 38077354

Authors

Shiya Yao

Yuejun Han

Mengxiang Yang

Ketao Jin

Huanrong Lan

Affiliations

Soon will be listed here.

Abstract

Immunotherapy has revolutionized the conventional treatment approaches for colorectal cancer (CRC), offering new therapeutic prospects for patients. Liquid biopsy has shown significant potential in early screening, diagnosis, and postoperative monitoring by analyzing circulating tumor cells (CTC) and circulating tumor DNA (ctDNA). In the era of immunotherapy, liquid biopsy provides additional possibilities for guiding immune-based treatments. Emerging technologies such as mass spectrometry-based detection of neoantigens and flow cytometry-based T cell sorting offer new tools for liquid biopsy, aiming to optimize immune therapy strategies. The integration of liquid biopsy with immunotherapy holds promise for improving treatment outcomes in colorectal cancer patients, enabling breakthroughs in early diagnosis and treatment, and providing patients with more personalized, precise, and effective treatment strategies.

Citing Articles

Liquid Biopsy and Colorectal Cancer.

Aggarwal S, Chougle A, Talwar V, Shukla P, Rohtagi N, Verma A South Asian J Cancer. 2025; 13(4):246-250.

PMID: 40060351 PMC: 11888811. DOI: 10.1055/s-0044-1801753.

Predictive value of preoperative circulating tumor cells combined with hematological indexes for liver metastasis after radical resection of colorectal cancer.

Zhu T, Li Y, Li R, Zhang J, Zhang W Medicine (Baltimore). 2025; 104(2):e41264.

PMID: 39792713 PMC: 11730839. DOI: 10.1097/MD.0000000000041264.

Visualizing the Tumor Microenvironment: Molecular Imaging Probes Target Extracellular Matrix, Vascular Networks, and Immunosuppressive Cells.

Chan H, Kuo D, Shueng P, Chuang H Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770505 PMC: 11676442. DOI: 10.3390/ph17121663.

Dynamics of tumor in situ fluid circulating tumor DNA in recurrent glioblastomas forecasts treatment efficacy of immune checkpoint blockade coupled with low-dose bevacizumab.

Wang D, Zhang J, Bu C, Liu G, Guo G, Zhang Z J Cancer Res Clin Oncol. 2024; 150(10):466.

PMID: 39422764 PMC: 11489198. DOI: 10.1007/s00432-024-05997-8.

Strategies for treating the cold tumors of cholangiocarcinoma: core concepts and future directions.

Zhang G, Li J, Li G, Zhang J, Yang Z, Yang L Clin Exp Med. 2024; 24(1):193.

PMID: 39141161 PMC: 11324771. DOI: 10.1007/s10238-024-01460-7.

References

Tie J, Cohen J, Lo S, Wang Y, Li L, Christie M . Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies. Int J Cancer. 2020; 148(4):1014-1026. PMC: 8818130. DOI: 10.1002/ijc.33312. View

Singh T, Fatehi Hassanabad M, Hassanabad A . Non-small cell lung cancer: Emerging molecular targeted and immunotherapeutic agents. Biochim Biophys Acta Rev Cancer. 2021; 1876(2):188636. DOI: 10.1016/j.bbcan.2021.188636. View

Ito K, Schoder H, Teng R, Humm J, Ni A, Wolchok J . Prognostic value of baseline metabolic tumor volume measured on F-fluorodeoxyglucose positron emission tomography/computed tomography in melanoma patients treated with ipilimumab therapy. Eur J Nucl Med Mol Imaging. 2018; 46(4):930-939. PMC: 6451667. DOI: 10.1007/s00259-018-4211-0. View

Braune J, Keller L, Schiller F, Graf E, Rafei-Shamsabadi D, Wehrle J . Circulating Tumor DNA Allows Early Treatment Monitoring in BRAF- and NRAS-Mutant Malignant Melanoma. JCO Precis Oncol. 2022; 4:20-31. DOI: 10.1200/PO.19.00174. View

Kobayashi S, Nakamura Y, Taniguchi H, Odegaard J, Nomura S, Kojima M . Impact of Preoperative Circulating Tumor DNA Status on Survival Outcomes After Hepatectomy for Resectable Colorectal Liver Metastases. Ann Surg Oncol. 2021; 28(8):4744-4755. DOI: 10.1245/s10434-020-09449-8. View

Taniguchi H, Nakamura Y, Kotani D, Yukami H, Mishima S, Sawada K . CIRCULATE-Japan: Circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer. Cancer Sci. 2021; 112(7):2915-2920. PMC: 8253296. DOI: 10.1111/cas.14926. View

Kim K, Cho J, Ku B, Koh J, Sun J, Lee S . The First-week Proliferative Response of Peripheral Blood PD-1CD8 T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors. Clin Cancer Res. 2019; 25(7):2144-2154. DOI: 10.1158/1078-0432.CCR-18-1449. View

Zhang Q, Luo J, Wu S, Si H, Gao C, Xu W . Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade. Cancer Discov. 2020; 10(12):1842-1853. PMC: 8358981. DOI: 10.1158/2159-8290.CD-20-0047. View

Mouliere F, El Messaoudi S, Pang D, Dritschilo A, Thierry A . Multi-marker analysis of circulating cell-free DNA toward personalized medicine for colorectal cancer. Mol Oncol. 2014; 8(5):927-41. PMC: 5528519. DOI: 10.1016/j.molonc.2014.02.005. View

10.

Faulkner L, Howells L, Pepper C, Shaw J, Thomas A . The utility of ctDNA in detecting minimal residual disease following curative surgery in colorectal cancer: a systematic review and meta-analysis. Br J Cancer. 2022; 128(2):297-309. PMC: 9902552. DOI: 10.1038/s41416-022-02017-9. View

11.

Cobbold M, De La Pena H, Norris A, Polefrone J, Qian J, English A . MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia. Sci Transl Med. 2013; 5(203):203ra125. PMC: 4071620. DOI: 10.1126/scitranslmed.3006061. View

12.

Willis J, Lefterova M, Artyomenko A, Kasi P, Nakamura Y, Mody K . Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel. Clin Cancer Res. 2019; 25(23):7035-7045. DOI: 10.1158/1078-0432.CCR-19-1324. View

13.

Dudley J, Lin M, Le D, Eshleman J . Microsatellite Instability as a Biomarker for PD-1 Blockade. Clin Cancer Res. 2016; 22(4):813-20. DOI: 10.1158/1078-0432.CCR-15-1678. View

14.

Mika T, Thomson J, Nilius-Eliliwi V, Vangala D, Baraniskin A, Wulf G . Quantification of cell-free DNAfor the analysis of CD19-CAR-T cells during lymphoma treatment. Mol Ther Methods Clin Dev. 2021; 23:539-550. PMC: 8606297. DOI: 10.1016/j.omtm.2021.10.009. View

15.

Raza A, Khan A, Inchakalody V, Mestiri S, Yoosuf Z, Bedhiafi T . Dynamic liquid biopsy components as predictive and prognostic biomarkers in colorectal cancer. J Exp Clin Cancer Res. 2022; 41(1):99. PMC: 8922757. DOI: 10.1186/s13046-022-02318-0. View

16.

De Mattos-Arruda L, Mayor R, Ng C, Weigelt B, Martinez-Ricarte F, Torrejon D . Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun. 2015; 6:8839. PMC: 5426516. DOI: 10.1038/ncomms9839. View

17.

Chang J, Lin G, Ye M, Tong D, Zhao J, Zhu D . Decreased mean platelet volume predicts poor prognosis in metastatic colorectal cancer patients treated with first-line chemotherapy: results from mCRC biomarker study. BMC Cancer. 2019; 19(1):15. PMC: 6322328. DOI: 10.1186/s12885-018-5252-2. View

18.

Oliveira-Ferrer L, Legler K, Milde-Langosch K . Role of protein glycosylation in cancer metastasis. Semin Cancer Biol. 2017; 44:141-152. DOI: 10.1016/j.semcancer.2017.03.002. View

19.

Rossi G, Russo A, Tagliamento M, Tuzi A, Nigro O, Vallome G . Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient. Cancers (Basel). 2020; 12(5). PMC: 7281184. DOI: 10.3390/cancers12051125. View

20.

Yao S, Lan H, Han Y, Mao C, Yang M, Zhang X . From organ preservation to selective surgery: How immunotherapy changes colorectal surgery?. Surg Open Sci. 2023; 15:44-53. PMC: 10450522. DOI: 10.1016/j.sopen.2023.07.024. View